Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Cutaneous Lupus Erythematosus

In brief

The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).

Key facts

Study ID

NCT04809623

Run by

Gilead Sciences

People needed

3

Starts

2021-09-01

Expected to finish

2022-10-18

Last updated by the study team

2024-04-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Wallace Rheumatic Studies Center, LLC — Beverly Hills, California, United States
• Clinical Research of West Florida, Inc. — Clearwater, Florida, United States
• Dawes Fretzin Clincial Research Group, LLC — Indianapolis, Indiana, United States
• DJL Clinical Research, PLLC — Charlotte, North Carolina, United States
• Metroplex Clinical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.